scholarly journals Controlling Alzheimer’s Disease Through the Deep Brain Stimulation to Thalamic Relay Cells

2021 ◽  
Vol 15 ◽  
Author(s):  
XiaoLi Yang ◽  
RuiXi Zhang ◽  
ZhongKui Sun ◽  
Jürgen Kurths

Experimental and clinical studies have shown that the technique of deep brain stimulation (DBS) plays a potential role in the regulation of Alzheimer’s disease (AD), yet it still desires for ongoing studies including clinical trials, theoretical approach and action mechanism. In this work, we develop a modified thalamo-cortico-thalamic (TCT) model associated with AD to explore the therapeutic effects of DBS on AD from the perspective of neurocomputation. First, the neuropathological state of AD resulting from synapse loss is mimicked by decreasing the synaptic connectivity strength from the Inter-Neurons (IN) neuron population to the Thalamic Relay Cells (TRC) neuron population. Under such AD condition, a specific deep brain stimulation voltage is then implanted into the neural nucleus of TRC in this TCT model. The symptom of AD is found significantly relieved by means of power spectrum analysis and nonlinear dynamical analysis. Furthermore, the therapeutic effects of DBS on AD are systematically examined in different parameter space of DBS. The results demonstrate that the controlling effect of DBS on AD can be efficient by appropriately tuning the key parameters of DBS including amplitude A, period P and duration D. This work highlights the critical role of thalamus stimulation for brain disease, and provides a theoretical basis for future experimental and clinical studies in treating AD.

2021 ◽  
pp. 1-18
Author(s):  
Yu-si Chen ◽  
Kai Shu ◽  
Hui-cong Kang

Alzheimer’s disease (AD) is becoming a prevalent disease in the elderly population. Past decades have witnessed the development of drug therapies with varying targets. However, all drugs with a single molecular target fail to reverse or ameliorate AD progression, which ultimately results in cortical and subcortical network dysregulation. Deep brain stimulation (DBS) has been proven effective for the treatment of Parkinson’s disease, essential tremor, and other neurological diseases. As such, DBS has also been gradually acknowledged as a potential therapy for AD. The current review focuses on DBS of the nucleus basalis of Meynert (NBM). As a critical component of the cerebral cholinergic system and the Papez circuit in the basal ganglia, the NBM plays an indispensable role in the subcortical regulation of memory, attention, and arousal state, which makes the NBM a promising target for modulation of neural network dysfunction and AD treatment. We summarized the intricate projection relations and functionality of the NBM, current approaches for stereotactic localization and evaluation of the NBM, and the therapeutic effects of NBM-DBS both in patients and animal models. Furthermore, the current shortcomings of NBM-DBS, such as variations in cortical blood flow, increased temperature in the target area, and stimulation-related neural damage, were presented.


2018 ◽  
Vol 11 (2) ◽  
pp. 435-444 ◽  
Author(s):  
Amandeep Mann ◽  
Elise Gondard ◽  
Davide Tampellini ◽  
Jorge A.T. Milsted ◽  
Desiree Marillac ◽  
...  

2016 ◽  
Vol 30 (1) ◽  
pp. 70-72 ◽  
Author(s):  
David P. McMullen ◽  
Paul Rosenberg ◽  
Jennifer Cheng ◽  
Gwenn S. Smith ◽  
Constantine Lyketsos ◽  
...  

2010 ◽  
Vol 68 (4) ◽  
pp. 521-534 ◽  
Author(s):  
Adrian W. Laxton ◽  
David F. Tang-Wai ◽  
Mary Pat McAndrews ◽  
Dominik Zumsteg ◽  
Richard Wennberg ◽  
...  

2020 ◽  
Vol 8 (20) ◽  
pp. 4938-4945 ◽  
Author(s):  
Wei Lin ◽  
Wei-Qi Bao ◽  
Jing-Jie Ge ◽  
Li-Kun Yang ◽  
Zhi-Pei Ling ◽  
...  

2021 ◽  
Author(s):  
Paloma Abrantes de Oliveira ◽  
Diogo Abrantes de Oliveira ◽  
Isabelle Magalhães Guedes Freitas

INTRODUCTION: Alzheimer’s disease (AD) is a disorder characterized by cognitive impairment. The brain network in DA can be interrupted by deficiencies in glucose metabolismo. Deep brain stimulation (DBS) is used in Parkinson’s disease (PM), once it modulates motor circuits. Considering this potential, the benefits of this approach in DA must be evaluated1,2. OBJECTIVE: To investigate the potential benefit of stimulating the cerebral fornix (CF) through DBS for patients with AD. METHODS: Controlled and randomized clinical trials (ECCR), in English, performed on humans, in the last 5 years, indexed on PubMed, were selected from the keywords “Deep brain Stimulation” and “Alzheimer Dementia”. This review was registered on PROSPERO by protocol 254506 and the PRISMA recommendation was used to improve its organization. RESULTS: Deeb W et al. (2019) conducted an ECCR on 42 patients with AD receiving DBS in CF, anterior commissure, corpus and sub-corpus callosum, demonstrating that in 48% of them, old experiences were reported. Furthermore, the memories became better as the stimulation increased. Lozano AM et al. (2016), in turn, developed an ECCR on 6 patients receiving DBS in CF, showing increases in glucose metabolism in some cerebral areas after 12 months, contrasting to the expected reduction in AD, especially in > 65 years. It’s noteworthy that the multicenter and double-blind ECCR by Ponce FA (2016) showed the safety of DBS in CF as therapy for AD, similar to that verified in the MP. CONCLUSION: The analyzed evidences suggest a potential cognitive benefit of DBS in the therapeutic management of AD.


Sign in / Sign up

Export Citation Format

Share Document